The Next Generation Biotech Media
By Pavel Ryzhov, Ph.D. Acute myeloid leukemia (AML), a type of blood cancer, is an aggressive disease affecting 3-5 people per 100,000 cases in the US. The buildup of immature …
Read More
By Rajaneesh K. Gopinath, Ph.D. Evading the vigil of our immune system is a hallmark of cancer, and tumor cells achieves it through multiple mechanisms. Immunotherapy is the endeavor of …
Read More
By Nashrah Ahmad, Ph.D. Candidate & Rajaneesh K. Gopinath, Ph.D. Introduction As the second most common blood cancer in the United States, multiple myeloma has proved to be a huge …
Read More
On 1st September, Gilead Sciences announced a strategic collaboration with Jounce Therapeutics to grab an exclusive license agreement for a novel immunotherapy program. By Ruchi Jhonsa, Ph.D. Founded with a …
Read More
By Nashrah Ahmad, Ph.D. Candidate Introduction Daratumumab, an anti-CD38 monoclonal antibody, has revolutionized the treatment outcome and prognostic expectations in patients with relapsed myeloma. The USFDA approved it in November …
Read More
After registering positive results in Phase 3, QUAZAR AML-001 trial, the company would be expecting the oral hypomethylating agent to notch FDA authorization this week. By Pavel Ryzhov, Ph.D. In …
Read More
A recent study published in the journal Cancer Research by University of Bath researchers demonstrates a new imaging technique that can predict the response of anti-PD-1 therapy by looking into …
Read More
On August 24th, Merck announced its anti-PD-1 therapy received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency for treating unresectable, advanced or recurrent esophageal squamous cell carcinoma …
Read More
The Series C financing was led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors. The funds will be used to advance the PREEMPT CRC™ clinical trial …
Read More
The Cambridge, UK-based cancer diagnostics company which was founded in early 2019, plans to use the funds to advance the development, clinical validation, and commercialization of oncology panels to enable precision …
Read More